Recently, Changzhou Hengbang Pharmaceutical Co., Ltd., the production base of Hansoh Pharma, has received its first certification to the ISO 50001 standard for energy management systems. Up to now, the production base of Hansoh Pharma has been fully certified to the ISO 50001 standard for energy management systems and the ISO 14001 standard for environmental management systems, which marks that the company has achieved significant results in scientific, procedural and standardized energy conservation, emission reduction and energy performance management and has reached an energy management level meeting internationally advanced standards. 

Helping achieve the double carbon targets while working towards a green future Guided by the strategic goal to achieve carbon peaking by 2030 and carbon neutrality by 2060, China's economic and social development has entered a stage of comprehensive green transformation, and energy transition has become an important engine for achieving the double carbon targets. Always adhering to the sustainable development approach, Hansoh Pharma has taken active response measures and leveraged its own strength in technological innovation to fulfil its environmental commitments in multiple dimensions. ISO50001 is a voluntary international standard that outlines not only models for strategic energy management practices but also scientific methods for clean energy actions in response to climate change risks. It is a powerful certification for businesses' continuous improvement of energy use efficiency and level, reduction in energy costs and carbon emissions, fulfillment of social and environmental commitments, and efficient and scientific use of energy.During the establishment of its ISO50001 energy management system, Hansoh Pharma has done a lot of effective work, developed a number of environmentally sustainable goals and action plans with respect to greenhouse gas emission reduction, energy efficiency improvement and waste gas emission reduction, and adopted environmental protection and low carbon approaches throughout the whole process of product development, manufacturing and sales. In addition, Hansoh Pharma has extended its environmental requirements to its supplier management and evaluation criteria, and on the basis built a green supply chain in an all-round way. Up to now, all of Hansoh Pharma's energy management initiatives have achieved positive results, reinforcing the company's determination and goal towards a green, energy-efficient and low-carbon future. Aligning ESG practices with international standards to drive sustainable development As a global innovation-driven pharmaceutical company, Hansoh Pharma is faced with complex and diverse ESG challenges and opportunities. To keep ESG governance aligned with international standards, Hansoh Pharma has established a long-term ESG improvement mechanism and built a complete ESG governance structure consisting of decision-making, management and executive levels on the basis of UN SDGs, TCFD recommendations and mainstream ESG governance frameworks, so as to ensure the effective implementation and sustainable execution of work at all levels. Based on the outstanding results of ESG performance management, Hansoh Pharma's MSCI ESG rating has been upgraded for two consecutive years and included in the Dow Jones Sustainability Index and the HSCEI ESG Index, fully demonstrating the company's competitiveness in sustainable development. Through continuous innovation in ESG practices, Hansoh Pharma has been successively recognized as one of Businesses with Green Supply Chain Management, National-Level Green Factories and Excellent CSR Projects of Chinese Pharmaceutical Companies, which reflects the full recognition of Hansoh Pharma's CSR fulfillment and sustainability value by various rating agencies. There is a long way ahead to save energy and increase efficiency. Under the global trend towards carbon neutrality, carbon emission reduction and sustainable development, Hansoh Pharma has always been committed to continuously improving its sustainability competitiveness through ESG governance, further fulfilling its commitments to patients, employees, investors, communities and the environment, bringing more ecological and social benefits, and helping to promote China's green development to a new level. Furthermore, Hansoh Pharma will live up to its health commitment, continue its focus on unmet clinical needs and cutting-edge technologies, enhance its technological innovation and research capabilities, accelerate its go-global strategy, and make greater contributions to the ambitious goal of Healthy China 2030 and the health and well-being of humans.